- Report
- February 2024
- 100 Pages
Asia Pacific
From €4386EUR$4,750USD£3,712GBP
- Report
- February 2024
- 80 Pages
Europe
From €4386EUR$4,750USD£3,712GBP
- Report
- February 2024
- 90 Pages
Asia Pacific
From €4386EUR$4,750USD£3,712GBP
- Report
- February 2024
- 80 Pages
Latin America
From €4386EUR$4,750USD£3,712GBP
- Report
- August 2023
- 70 Pages
Spain
From €4386EUR$4,750USD£3,712GBP
- Report
- August 2023
- 80 Pages
Middle East, Africa
From €4386EUR$4,750USD£3,712GBP
- Report
- October 2022
- 70 Pages
Africa
From €4386EUR$4,750USD£3,712GBP
- Report
- May 2024
- 93 Pages
Global
From €13845EUR$14,995USD£11,718GBP
- Report
- January 2024
- 150 Pages
Global
From €4478EUR$4,850USD£3,790GBP
- Report
- September 2025
- 142 Pages
Global
From €3500EUR$4,061USD£3,066GBP
- Report
- January 2024
- 120 Pages
United States
€3232EUR$3,500USD£2,735GBP
- Report
- February 2024
- 95 Pages
Global
From €3500EUR$4,061USD£3,066GBP
- Report
- February 2024
- 93 Pages
Global
From €3500EUR$4,061USD£3,066GBP
- Report
- July 2023
- 89 Pages
Global
From €3500EUR$4,061USD£3,066GBP

Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used to treat type 2 diabetes. It is a member of the Endocrine and Metabolic Disorders Drugs class, which are used to treat a variety of conditions related to hormones and metabolism. Lixisenatide works by stimulating the release of insulin from the pancreas, helping to reduce blood sugar levels. It is typically used in combination with other diabetes medications, such as metformin or sulfonylureas.
Lixisenatide is available in both injectable and oral formulations. The injectable form is administered once daily, while the oral form is taken once weekly. Common side effects of lixisenatide include nausea, diarrhea, and headache. It is important to note that lixisenatide should not be used in patients with type 1 diabetes or diabetic ketoacidosis.
Some companies in the Lixisenatide market include Sanofi, Eli Lilly, and Novo Nordisk. Show Less Read more